24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825
Fax: (361)578-5500

Medical Disorders
Resources
Basic InformationLookupsLatest News
AHA News: Inherited High Cholesterol May Be Common in People With Heart DiseaseDVT Clots Strike Many Critically Ill COVID-19 Patients: StudyYour Eyewear and COVID-19 SafetyPandemic Having More Impact on U.S. Hospitals Than Thought: StudyBig Need for Blood Donations as Postponed Surgeries ResumeAs Hard-Hit Areas of America Show Slowing in Coronavirus Cases, Other Regions See SpikesHydroxychloroquine May Worsen Odds for Cancer Patients With COVID-191 in 10 Hospitalized COVID-19 Patients With Diabetes Dies: StudyAHA News: How Bacteria in Your Gut Interact With the Mind and BodyMusic Might Help Soothe Ailing HeartsCould an Injected Electrode Control Your Pain Without Drugs?100,000 Dead, 40 Million Unemployed: America Hits Grim Pandemic MilestonesFDA Approves IV Artesunate for Severe Malaria'Silent' COVID-19 More Widespread Than ThoughtDrug Combos May Be Advance Against Heart FailurePollen Fragments Linger After Rains, Leaving Allergy Sufferers MiserableA New Hip or Knee Can Do a Marriage Good, Study FindsOnly Half of Americans Say They'd Get a Coronavirus Vaccine: SurveyAlzheimer's Gene Linked to Severe COVID-19 RiskCoronavirus Cases Ticking Upwards in Nearly a Dozen U.S. StatesLockdown Got You Down? Experts Offer Tips to De-StressCould a Hormone Help Spur High Blood Pressure?Nursing Homes Are Ground Zero for COVID-19Getting Back to Work Safely After LockdownRemdesivir Will Not Be Enough to Curb COVID-19, Study FindsOutdoor Swimming Pools Not a COVID-19 Risk: ExpertStrokes Are Deadlier When They Hit COVID-19 PatientsAHA News: How to Accurately Measure Blood Pressure at HomeU.S. Earmarks $1.2 Billion for New Vaccine Deal as Coronavirus Deaths Near 95,000During the Pandemic, How Safe Is the Great American Summer Vacation?COVID-19 Damages Lungs Differently From the Flu: StudyMore Evidence Hydroxychloroquine Won't Help, May Harm COVID-19 PatientsYour Sleep Habits May Worsen Your AsthmaExtra Pounds Could Bring More Painful JointsCOVID Can Complicate Pregnancy, Especially If Mom Is ObeseWHO Predicts COVID-19 Will Take Heavy Toll in AfricaCombining Remdesivir With Other Meds Could Boost COVID-Fighting PowerMultiple Sclerosis Ups Odds for Heart Trouble, StrokeAHA News: Not Wanting to Burden Busy Hospitals, She Disregarded Heart Attack SignsExperimental Vaccines Shield Monkeys From CoronavirusHeart Attack Cases at ERs Fall by Half – Are COVID Fears to Blame?Asthma Ups Ventilator Needs of Younger Adults With COVID-19: Study1 in 5 Hospitalized NYC COVID-19 Patients Needed ICU CareObesity Ups Odds for Dangerous Lung Clots in COVID-19 PatientsDoes 6 Feet Provide Enough COVID Protection?COVID-19 Antibodies May Tame Inflammatory Condition in Kids: StudyAs Americans Return to Work, How Will COVID Change the Workplace?COVID and Hypochondria: Online Therapy May Help Ease FearsAHA News: Is High Blood Pressure Inevitable?People Mount Strong Immune Responses to Coronavirus, Boding Well for a Vaccine
Questions and AnswersLinks
Related Topics

Diabetes

Trials Begin for Potential COVID-19 Drug Remdesivir

HealthDay News
by By Amy Norton
HealthDay Reporter
Updated: Apr 6th 2020

new article illustration

MONDAY, April 6, 2020 (HealthDay News) -- A drug originally developed to treat Ebola is getting a second chance in the spotlight, as research teams in the United States, Asia and Europe race to test it against the new coronavirus.

The drug, called remdesivir, has already been given to a limited number of patients hospitalized with COVID-19, on a "compassionate use" basis. That included the first U.S. patient diagnosed with the disease -- a 35-year-old man in Washington state who sought care on Jan. 19, shortly after returning home from Wuhan, China.

He ended up in the hospital, and after his lung function deteriorated, he was placed on oxygen and later given an infusion of remdesivir. He improved the next day, his doctors reported recently in the New England Journal of Medicine.

The problem is, individual cases do not prove that a treatment works, or would even be safe if given to large numbers of patients.

"You can't assume it's safe and effective," said Dr. Babafemi Taiwo, chief of infectious diseases at Northwestern University Feinberg School of Medicine, in Chicago.

This week, Northwestern was among the latest U.S. medical centers to join a large-scale research effort sponsored by the U.S. National Institute of Allergy and Infectious Diseases (NIAID). It is putting remdesivir to the "gold standard" test in medicine: a controlled clinical trial.

Patients hospitalized with COVID-19 are being randomly assigned to receive either infusions of remdesivir or a placebo, in addition to standard care, including breathing support.

Dr. Victor Tapson is a pulmonary medicine specialist at Cedars-Sinai Medical Center, in Los Angeles. He explained that "we don't learn whether something really works without randomized clinical trials."

Cedars-Sinai also joined the NIAID trial this week, becoming one of a planned 75 sites worldwide to participate. Tapson is the hospital's site director, where the goal is to enroll up to 30 patients.

All of the trial patients will be sick enough to be hospitalized, but at varying stages of severity, according to Tapson. Some will be intensive care unit (ICU) patients on ventilators, while others will be less ill -- showing low oxygen levels, for example.

At Northwestern, the first patient slated to receive the drug was an 89-year-old man in the ICU. His family is "very excited," Taiwo said. At the same time, he cautioned that everyone needs to wait for the trial results to know whether remdesivir can truly fight the virus.

The drug, made by U.S. biotech giant Gilead Sciences, was originally developed to battle the Ebola virus epidemic that swept through several African countries between 2013 and 2016. Clinical trials later showed it was less effective in treating the disease than some other experimental therapies.

"It might not be the most effective treatment for Ebola, but we did learn about its safety in humans," Tapson said.

And while Ebola is not caused by a coronavirus, animal research shows that remdesivir is active against the coronaviruses that caused the SARS (severe acute respiratory syndrome) and MERS (Middle East respiratory syndrome) outbreaks.

The drug has the potential to fight different virus families because of the way it works, Taiwo explained. Essentially, it disables key molecular machinery that certain viruses use to make copies of themselves.

In the latest trial, patients assigned to remdesivir will get a daily infusion of the drug for up to 10 days; those in the placebo group will receive infusions of an identical-looking, inactive substance.

Tapson could not predict when the results will be available, but it will be quick relative to the norm for clinical trials.

"We're not looking at how patients do in a year," Tapson said. "Once we have the one-month data, then data analysis can start."

Remdesivir is one of many treatments researchers are investigating for COVID-19. Other drugs, including antivirals and medications that target lung inflammation, are under study. And hospitals in New York City and Houston are looking at whether antibodies from the blood of recovered COVID-19 patients can be used to treat others.

Meanwhile, on March 28, the U.S. Food and Drug Administration said doctors can use two malaria drugs, hydroxychloroquine and chloroquine, to treat people hospitalized for COVID-19. That was based, however, on scant evidence that they are helpful -- primarily from a French study of 20 patients given hydroxychloroquine, with or without the antibiotic azithromycin.

A larger clinical trial to test hydroxychloroquine is underway.

None of the therapies under study are seen as a potential magic bullet. Tapson said it is "likely a multi-faceted approach will be ideal." And both he and Taiwo emphasized that prevention remains the primary weapon.

"We're working as fast as we can on treatments," Taiwo said. "But prevention is the best strategy we have."

More information

For the latest updates on COVID-19, visit the U.S. National Institutes of Health.